Skip to search formSkip to main contentSkip to account menu

GW 572016

Known as: GW-572016, GW572016 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

lapatiniblapatinib ditosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
BACKGROUND The dual kinase inhibitor lapatinib (Tykerb) has been applied for advanced breast cancer. However, the effectiveness… 
2006
2006
Canonical WNT signaling pathway and human AREG.
AREG (Amphiregulin), BTC (beta-cellulin), EGF, EPGN (Epigen), EREG (Epiregulin), HBEGF, NRG1, NRG2, NRG3, NRG4 and TGFA (TGFalpha… 
2006
2006
Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 )
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… 
2005
2005
Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
The majority of malignant pleural mesotheliomas (MPMs) aberrantly express the epidermal growth factor receptor (ErbB1). We… 
2005
2005
Current and future perspectives on fulvestrant.
Fulvestrant, an estrogen receptor antagonist with no known agonist effects, is effective and well tolerated in the treatment of… 
2004
2004
Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.
3070 Background. GW572016 (GW), a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, which induces growth arrest and/or… 
Review
2004
Review
2004
A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma…
4615 Background: GW572016 is an oral, reversible, dual inhibitor of ErbB1 and ErbB2 receptors. This multicenter, phase II trial… 
2004
2004
An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine
3081 Background: GW572016 is an oral, dual EGFR/ErbB2 tyrosine kinase inhibitor that blocks signal transduction pathways… 
2004
2004
An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole.
3071 Background: GW572016 is an oral, dual EGFR/ErbB2 tyrosine kinase inhibitor that blocks signal transduction pathways… 
2004
2004
Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016.
3823 In the current clinical oncology environment few anti-cancer agents are employed as stand alone therapies. With this in mind… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)